Get the Stockscreener App
17.90
0.89%
-0.16
After Hours:
18.32
0.42
+2.35%
Aktis Oncology Inc stock is traded at $17.90, with a volume of 224.15K.
It is down -0.89% in the last 24 hours and down -17.70% over the past month.
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. It has one operating segment focused on the research and development of targeted radiopharmaceuticals.
See More
Previous Close:
$18.06
Open:
$18.01
24h Volume:
224.15K
Relative Volume:
0.01
Market Cap:
$987.54M
Revenue:
$29.71M
Net Income/Loss:
$-69.15M
P/E Ratio:
-18.45
EPS:
-0.97
Net Cash Flow:
$-52.28M
1W Performance:
-8.53%
1M Performance:
-17.70%
6M Performance:
+48,018%
1Y Performance:
+48,018%
1-Day Range:
$17.37
$18.07
1-Week Range:
$16.80
$20.99
52-Week Range:
$16.80
$29.16
Aktis Oncology Inc Stock (AKTS) Company Profile
Compare AKTS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKTS
Aktis Oncology Inc
|
17.90 | 996.37M | 29.71M | -69.15M | -52.28M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Aktis Oncology Inc Stock (AKTS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-03-26 | Initiated | BofA Securities | Buy |
| Feb-03-26 | Initiated | JP Morgan | Overweight |
| Feb-03-26 | Initiated | Leerink Partners | Outperform |
| Feb-03-26 | Initiated | TD Cowen | Buy |
| Jan-04-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-06-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-24-23 | Initiated | B. Riley Securities | Buy |
| Feb-02-21 | Reiterated | Craig Hallum | Buy |
| Jan-15-21 | Reiterated | Craig Hallum | Buy |
| Sep-18-19 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jul-10-19 | Upgrade | Northland Capital | Market Perform → Outperform |
| May-13-19 | Reiterated | Craig Hallum | Buy |
| Feb-05-19 | Reiterated | Craig Hallum | Buy |
| Feb-05-19 | Downgrade | Northland Capital | Outperform → Market Perform |
| Dec-18-18 | Initiated | Craig Hallum | Buy |
| Nov-30-18 | Initiated | Lake Street | Buy |
| Jun-22-18 | Initiated | Loop Capital | Buy |
| Feb-09-18 | Initiated | Drexel Hamilton | Buy |
View All
Aktis Oncology Inc Stock (AKTS) Latest News
2026 kicks off with $10.8B January financing haul - BioWorld MedTech
Merck veteran Perlmutter-led Eikon Therapeutics valued at $860 million in Nasdaq debut - WTVB
Eikon’s $381M raise represents largest biopharma IPO in two years - BioWorld MedTech
IPO Tracker 2026: Eikon Clocks Largest IPO Since 2024, Generate, AgomAb Follow - BioSpace
Eikon Therapeutics raises $381M in IPO - Axios
Merck Veteran-Led Eikon Therapeutics Raises $381 Million in IPO - Bloomberg.com
Analysts Offer Insights on Healthcare Companies: Revvity (RVTY) and Aktis Oncology, Inc. (AKTS) - The Globe and Mail
Biopharma Co.'s Down-Round IPO May Signal More To Come - Law360
This GCI Liberty Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Tuesday - Benzinga
Aktis Oncology: Differentiated Miniprotein Radiopharma Platform Underpins Buy Rating and Multi-Billion Dollar Sales Potential - TipRanks
Merck veteran Perlmutter-led Eikon Therapeutics eyes $908 million valuation in IPO - Reuters
Eikon ?Therapeutics targets $908 million valuation in US IPO - marketscreener.com
Eikon sets $274M goal for upcoming stock market debut - Fierce Biotech
Carvina Capital: Strong Demand Lifts Aktis IPO - Barchart.com
Aktis Oncology prices IPO at $18 per share - MSN
Should You Buy PICS Stock After the PicPay IPO? - Barchart.com
Why Revolution Medicines Stock Surged by 11% Today - AOL.com
Huge Insider Buying Now at This Insurance Giant and 2 Biotechs - AOL.com
Investors Scoop Up Shares in Key Insurance and Biotech Companies - finance.coin-turk.com
‘No reasons to own’: Software stocks sink on fear of new AI tool - The Japan Times
Assessing Aktis Oncology (AKTS) Valuation After IPO, NASDAQ Inclusion And Heavy Insider And Institutional Buying - Yahoo Finance
AKTS SEC FilingsAKTIS ONCOLOGY INC 10-K, 10-Q, 8-K Forms - Stock Titan
United StatesGoodwin Advises Aktis Oncology In Closing Of $365.4 Million Upsized Initial Public Offering And Full Exercise Of Underwriters’ Option To Purchase Additional Shares - Mondaq
Wednesday Insider Activity: Mitsui’s $55.6M Berkley Buy Leads the Pack - Investing.com Nigeria
Wednesday Insider Activity: Mitsui’s $55.6M Berkley Buy Leads the Pack By Investing.com - Investing.com South Africa
Biotech Venture Limped Through 2025. A Brighter 2026 Beckons. - The Wall Street Journal
Insiders Make Bold Move as Key Players Double Down on Aktis Oncology - TipRanks
Aktis Oncology director Foley buys $4.19 million in shares By Investing.com - Investing.com India
Aktis Oncology: Mpm funds buy shares worth $20m By Investing.com - Investing.com Nigeria
Aktis Oncology: Mpm funds buy shares worth $20m - Investing.com
Aktis Oncology (AKTS) sees $20 million purchase by 10% owner - Investing.com South Africa
Aktis Oncology (AKTS) sees $20 million purchase by 10% owner By Investing.com - Investing.com Nigeria
Hedge Fund and Insider Trading News: Crispin Odey, Bill Ackman, Warren Buffett, Ray Dalio, ExodusPoint Capital, Saba Capital Management, Aktis Oncology Inc (AKTS), Warrior Met Coal Inc (HCC), and More - Insider Monkey
A Fresh IPO That Long-Term Investors Shouldn’t Ignore - Investing.com
A Fresh IPO That Long-Term Investors Shouldn't Ignore - Finviz
A Fresh IPO That Long-Term Investors Shouldn’t Ignore - Yahoo Finance
Aktis Oncology director Nodelman buys $40 million in shares By Investing.com - Investing.com Australia
Assessing Aktis Oncology (AKTS) Valuation After Recent Share Price Movement And Ongoing Losses - simplywall.st
Insider Stock Purchases: January 13, 2026 - Quiver Quantitative
Aktis Oncology Stock (AKTS) Opinions on Upsized IPO - Quiver Quantitative
Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Upcoming Events - FinancialContent
Tuesday 1/13 Insider Buying Report: AKTS, MSTR - Nasdaq
RTW Biotech Opp.Aktis announces $318 million IPO - Research Tree
Inside Biotech: Eikon Therapeutics joins IPO queue with late-stage oncology focus - Proactive financial news
Major Insider Moves Signal Growing Confidence in Aktis Oncology - TipRanks
Aktis Oncology director Nodelman buys $40 million in shares - Investing.com
Aktis Oncology Inc Stock (AKTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aktis Oncology Inc Stock (AKTS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MPM BIOVENTURES 2018, L.P. | 10% Owner |
Jan 12 '26 |
Buy |
18.00 |
1,112,777 |
20,029,986 |
10,260,064 |
| GADICKE ANSBERT | 10% Owner |
Jan 12 '26 |
Buy |
18.00 |
1,112,777 |
20,029,986 |
10,260,064 |
| EcoR1 Capital, LLC | Director |
Jan 12 '26 |
Buy |
18.00 |
2,222,222 |
39,999,996 |
4,348,658 |
| Vida Ventures II, LLC | 10% Owner |
Jan 12 '26 |
Buy |
18.00 |
835,000 |
15,030,000 |
5,671,825 |
| Kim Helen Susan | Director |
Jan 12 '26 |
Buy |
18.00 |
835,000 |
15,030,000 |
5,671,825 |
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):